Another combination therapy treatment was encorafenib and binimetinib, which was studied in the COLUMBUS (study of encorafenib plus binimetinib versus encorafenib versus vemurafenib in metastatic melanoma) trial (Dummer et al., 2018), which screened patients with advanced unresectable or metastatic melanoma which is BRAF V600 mutation positive. The gene discussed is BRAF; the disease is metastatic melanoma.